Leukemia Clinical Trials in Glasgow

10 recruitingGlasgow, United Kingdom

Showing 110 of 10 trials

Recruiting
Phase 3

A Long-term Extension Study of PCI-32765 (Ibrutinib)

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled174 locationsNCT01804686
Recruiting
Phase 2

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Loxo Oncology, Inc.249 enrolled133 locationsNCT06588478
Recruiting
Phase 3

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Adult Acute Myeloid Leukemia
Priothera SAS366 enrolled108 locationsNCT05429632
Recruiting
Phase 1

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

Chronic Myeloid LeukemiaCMLChronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Enliven Therapeutics200 enrolled46 locationsNCT05304377
Recruiting
Phase 1Phase 2

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Acute Myeloid LeukemiaNon-Hodgkin LymphomaMultiple Myeloma+3 more
CellCentric Ltd.250 enrolled39 locationsNCT04068597
Recruiting
Phase 1Phase 2

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

Solid TumorsAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+6 more
Incyte Biosciences International Sàrl70 enrolled25 locationsNCT03934372
Recruiting
Phase 1Phase 2

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAdvanced Malignant Neoplasm+4 more
Kura Oncology, Inc.263 enrolled56 locationsNCT04067336
Recruiting
Phase 3

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Leukemia, Acute Lymphoblastic
Mats Heyman6,430 enrolled130 locationsNCT04307576
Recruiting
Phase 3

Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

Acute Myeloid Leukemia
Stichting Hemato-Oncologie voor Volwassenen Nederland227 enrolled119 locationsNCT07075016
Recruiting
Phase 3

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Acute Myeloid Leukemia, Adult
Stichting Hemato-Oncologie voor Volwassenen Nederland415 enrolled67 locationsNCT06652438